The FDA recently put the spotlight on the concerning side effects of marketed PI3K inhibitors for blood cancers. Similarly, investigators in the U.K. recorded a high level of side effects among head and neck cancer patients taking an experimental PI3K inhibitor by Amgen in a clinical trial.
Apnimed isn’t resting on its laurels. A year after its series B financing, the clinical-stage pharmaceutical has closed a $62.5 million series C round designed to push its obstructive sleep apnea (OSA) drug into phase 3 trials.
Biogen’s CEO is out. Aduhelm is, essentially, on its last legs. So what’s in? Lecanemab, the monoclonal antibody that the pharma hopes can reset some of the mistakes of the past.
Confidence in Kezar Life Sciences’ vision for zetomipzomib as the one inflammatory disorder drug to rule them all just took a hit, with the failure to beat placebo in a midphase rare autoimmune disease clinical trial sending the stock spiraling down.
Chasing Bristol Myers and Pfizer, Connect fails phase 2 ulcerative colitis trial but spies path forward
Connect Biopharma’s pursuit of Bristol Myers Squibb and Pfizer has hit trouble, with a midphase failure in ulcerative colitis sending the biotech’s stock down over 30% to $1.30 apiece in premarket trading despite its positive spin on the results.
Bristol Myers Squibb and Merck KGaA are diving deeper into the protein degradation pool, with both inking partnerships with Amphista Therapeutics that together could bring in $2.3 billion for the British biotech.
Catalio Capital Management, the life sciences investment firm behind recent funding rounds from Pheast Therapeutics, Octant and more, has reloaded with another $381 million—its largest fund to date to support breakthrough biotech companies.
Another of Pfizer’s gene therapies has been freed from an FDA clinical hold, but the study is not set to get underway immediately.
Sierra Oncology was ready to take momelotinib to the market, but it needed help. What started out as an effort to find a strategic partner turned into a $1.9 billion buyout from GlaxoSmithKline, which didn’t just want an arm’s-length deal. Chief Commercial Officer Luke Miels wanted it all.
After a brutal 2021 that included an FDA rejection reportedly stemming from trial misconduct, Sesen Bio is looking for an exit route, including a possible sale.